• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Kinetic Determination of Cerebrospinal Fluid Adenosine Deaminase Activity for the Diagnosis of Tuberculous Meningitis.脑脊液腺苷脱氨酶活性的动力学测定在结核性脑膜炎诊断中的应用。
Am J Trop Med Hyg. 2024 Sep 3;111(5):1024-1026. doi: 10.4269/ajtmh.23-0555. Print 2024 Nov 6.
2
Adenosine deaminase and tuberculous meningitis--a systematic review with meta-analysis.腺苷脱氨酶与结核性脑膜炎——一项系统评价与荟萃分析
Scand J Infect Dis. 2010 Mar;42(3):198-207. doi: 10.3109/00365540903428158.
3
Adenosine deaminase from the cerebrospinal fluid for the diagnosis of tuberculous meningitis: A meta-analysis.脑脊液腺苷脱氨酶在结核性脑膜炎诊断中的作用:Meta 分析。
Trop Med Int Health. 2023 Mar;28(3):175-185. doi: 10.1111/tmi.13849. Epub 2023 Jan 20.
4
Diagnostic test accuracy of adenosine deaminase for tuberculous meningitis: A systematic review and meta-analysis.腺苷脱氨酶对结核性脑膜炎的诊断准确性:系统评价和荟萃分析。
J Infect. 2017 Jun;74(6):545-554. doi: 10.1016/j.jinf.2017.02.012. Epub 2017 Mar 31.
5
Diagnostic value of adenosine deaminase in cerebrospinal fluid for tuberculous meningitis: a meta-analysis.腺苷脱氨酶在脑脊液中对结核性脑膜炎的诊断价值:一项荟萃分析。
Int J Tuberc Lung Dis. 2010 Nov;14(11):1382-7.
6
Central Inflammatory Cytokines in Tuberculous Meningitis: A Systematic Review and Meta-analysis.结核性脑膜炎中的中枢炎症细胞因子:系统评价与荟萃分析
J Interferon Cytokine Res. 2022 Mar;42(3):95-107. doi: 10.1089/jir.2021.0176.
7
[Cerebrospinal fluid adenosine deaminase and its dynamic changes in tuberculous meningitis].[脑脊液腺苷脱氨酶及其在结核性脑膜炎中的动态变化]
Zhonghua Jie He He Hu Xi Za Zhi. 2017 May 12;40(5):339-342. doi: 10.3760/cma.j.issn.1001-0939.2017.05.005.
8
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
9
Xpert MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.用于肺外结核病和利福平耐药性的Xpert MTB/RIF检测
Cochrane Database Syst Rev. 2018 Aug 27;8(8):CD012768. doi: 10.1002/14651858.CD012768.pub2.
10
Value of adenosine deaminase (ADA) in ascitic fluid for the diagnosis of tuberculous peritonitis: a meta-analysis.腹水腺苷脱氨酶(ADA)在结核性腹膜炎诊断中的价值:一项荟萃分析
J Clin Gastroenterol. 2006 Sep;40(8):705-10. doi: 10.1097/00004836-200609000-00009.

本文引用的文献

1
Evaluation of seegene anyplex MTB/NTM real-time detection assay for diagnosis of tuberculous meningitis.评估赛沛 Anyplex MTB/NTM 实时检测试剂盒在结核性脑膜炎诊断中的应用。
Orphanet J Rare Dis. 2024 Jan 3;19(1):7. doi: 10.1186/s13023-023-03009-5.
2
Determination of cerebrospinal fluid adenosine deaminase activity cut-off for the diagnosis of tuberculous meningitis in Hong Kong.确定香港地区结核性脑膜炎诊断中脑脊液腺苷脱氨酶活性的临界值
J Clin Pathol. 2020 Dec;73(12):800-802. doi: 10.1136/jclinpath-2019-206397. Epub 2020 May 18.
3
Determination and Validation of a Lower Cut Off Value of Cerebrospinal Fluid Adenosine Deaminase (CSF-ADA) Activity in Diagnosis of Tuberculous Meningitis.脑脊液腺苷脱氨酶(CSF-ADA)活性下限值在结核性脑膜炎诊断中的确定与验证
J Clin Diagn Res. 2017 Apr;11(4):OC22-OC24. doi: 10.7860/JCDR/2017/25823.9625. Epub 2017 Apr 1.
4
Diagnostic test accuracy of adenosine deaminase for tuberculous meningitis: A systematic review and meta-analysis.腺苷脱氨酶对结核性脑膜炎的诊断准确性:系统评价和荟萃分析。
J Infect. 2017 Jun;74(6):545-554. doi: 10.1016/j.jinf.2017.02.012. Epub 2017 Mar 31.
5
Recent advances in the diagnosis and management of tuberculous meningitis.结核性脑膜炎诊断与治疗的最新进展
Curr Opin Infect Dis. 2017 Feb;30(1):123-128. doi: 10.1097/QCO.0000000000000331.
6
Cerebrospinal fluid adenosine deaminase activity for the diagnosis of tuberculous meningitis in adults.脑脊液腺苷脱氨酶活性用于成人结核性脑膜炎的诊断
Southeast Asian J Trop Med Public Health. 2006 Sep;37(5):948-52.
7
Corticosteroid in tuberculous meningitis.皮质类固醇在结核性脑膜炎中的应用。
J Med Assoc Thai. 1996 Feb;79(2):83-90.
8
Adenosine deaminase activity in lymphocytes.
Br J Haematol. 1977 Sep;37(1):157-8.

脑脊液腺苷脱氨酶活性的动力学测定在结核性脑膜炎诊断中的应用。

Kinetic Determination of Cerebrospinal Fluid Adenosine Deaminase Activity for the Diagnosis of Tuberculous Meningitis.

机构信息

Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.

Clinical Laboratory Section, Srinagarind Hospital, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.

出版信息

Am J Trop Med Hyg. 2024 Sep 3;111(5):1024-1026. doi: 10.4269/ajtmh.23-0555. Print 2024 Nov 6.

DOI:10.4269/ajtmh.23-0555
PMID:39226903
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11542524/
Abstract

Tuberculous meningitis (TBM) is a common infectious disease of the central nervous system. Detection of cerebrospinal fluid (CSF) adenosine deaminase (ADA) activity for the diagnosis of TBM has a relatively high accuracy. Most previous reports determined ADA levels by following the colorimetric method of Giusti (endpoint assay). Recently, a Diazyme ADA assay kit was developed to determine CSF ADA levels. This study aimed to define the cutoff value of CSF ADA that is diagnostic for TBM with the Diazyme ADA assay kit. Adults with meningitis were included in the study. The diagnostic properties of CSF ADA for TBM as determined by the Diazyme ADA assay kit were assessed by the receiver operating characteristic curve, area under the curve, sensitivity, specificity, and likelihood ratios. There were 97 patients enrolled in the study, comprising 15 cases of TBM and 82 cases of non-TBM meningitis. The median CSF ADA activity level in the TBM group was significantly higher than in the non-TBM group (P = 0.002), with a mean difference of 14.5 U/L (95% CI: 5.3-23.8 U/L). A CSF ADA level of 6.1 U/L was the best cutoff value to differentiate between the TBM and non-TBM groups, with a sensitivity of 53.33%, a specificity of 89.02%, a positive likelihood ratio of 4.86, a negative likelihood ratio of 0.52, and an area under the curve of 0.75. A CSF ADA level of 6.1 U/L determined by the Diazyme ADA assay kit could be used as a diagnostic tool in the early diagnosis of TBM.

摘要

结核性脑膜炎(TBM)是一种常见的中枢神经系统感染性疾病。检测脑脊液(CSF)中的腺苷脱氨酶(ADA)活性对 TBM 的诊断具有较高的准确性。大多数先前的报告采用 Giusti 比色法(终点测定法)来确定 ADA 水平。最近,Diazyme ADA 测定试剂盒被开发出来用于确定 CSF ADA 水平。本研究旨在确定 Diazyme ADA 试剂盒检测 CSF ADA 对 TBM 的诊断界值。纳入了患有脑膜炎的成年人。通过受试者工作特征曲线、曲线下面积、敏感性、特异性和似然比评估 Diazyme ADA 测定试剂盒检测 CSF ADA 对 TBM 的诊断性能。本研究共纳入 97 例患者,包括 15 例 TBM 和 82 例非 TBM 脑膜炎。TBM 组 CSF ADA 活性水平明显高于非 TBM 组(P = 0.002),平均差异为 14.5 U/L(95%CI:5.3-23.8 U/L)。CSF ADA 水平为 6.1 U/L 是区分 TBM 和非 TBM 组的最佳界值,其敏感性为 53.33%,特异性为 89.02%,阳性似然比为 4.86,阴性似然比为 0.52,曲线下面积为 0.75。Diazyme ADA 试剂盒检测的 CSF ADA 水平为 6.1 U/L 可作为 TBM 早期诊断的诊断工具。